---
document_datetime: 2025-12-02 06:40:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-lilly.html
document_name: pemetrexed-lilly.html
version: success
processing_time: 0.1182102
conversion_datetime: 2025-12-25 07:43:22.400468
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pemetrexed Lilly

[RSS](/en/individual-human-medicine.xml/65654)

##### Withdrawn

This medicine's authorisation has been withdrawn

pemetrexed Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pemetrexed Lilly](#news-on)
- [More information on Pemetrexed Lilly](#more-information-on-pemetrexed-lilly-1041)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 1 November 2021, the marketing authorisation of Pemetrexed Lilly (pemetrexed) ceased to be valid in the European Union (EU). The cessation of validity is due to the fact that the marketing authorisation holder, Eli Lilly Nederland B.V., permanently discontinued marketing of Pemetrexed Lilly in the EU in October 2018.

In accordance with provisions of the sunset clause1, the marketing authorisation of a medicinal product lapses if the product had not been marketed in any of the EU Member States for three consecutive years. Eli Lilly Nederland B.V. confirmed that it discontinued the marketing of the product due to commercial reasons.

Pemetrexed Lilly was granted marketing authorisation in the EU on 14 September 2015 for treatment of malignant pleural mesothelioma and non-small cell lung cancer.

The marketing authorisation was initially valid for a 5-year period and was renewed with unlimited validity in 2020. Pemetrexed Lilly is a generic medicine of Alimta. There are other generic medicinal products of pemetrexed authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Pemetrexed Lilly is updated to indicate that the marketing authorisation is no longer valid.

Pemetrexed Lilly : EPAR - Summary for the public

Reference Number: EMA/509168/2015

English (EN) (744.06 KB - PDF)

**First published:** 02/10/2015

**Last updated:** 26/11/2021

[View](/en/documents/overview/pemetrexed-lilly-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-427)

български (BG) (781.53 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/bg/documents/overview/pemetrexed-lilly-epar-summary-public_bg.pdf)

español (ES) (661.66 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/es/documents/overview/pemetrexed-lilly-epar-summary-public_es.pdf)

čeština (CS) (728.98 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/cs/documents/overview/pemetrexed-lilly-epar-summary-public_cs.pdf)

dansk (DA) (688.21 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/da/documents/overview/pemetrexed-lilly-epar-summary-public_da.pdf)

Deutsch (DE) (662.44 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/de/documents/overview/pemetrexed-lilly-epar-summary-public_de.pdf)

eesti keel (ET) (660.26 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/et/documents/overview/pemetrexed-lilly-epar-summary-public_et.pdf)

ελληνικά (EL) (787.38 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/el/documents/overview/pemetrexed-lilly-epar-summary-public_el.pdf)

français (FR) (662.17 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/fr/documents/overview/pemetrexed-lilly-epar-summary-public_fr.pdf)

hrvatski (HR) (676.44 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/hr/documents/overview/pemetrexed-lilly-epar-summary-public_hr.pdf)

italiano (IT) (660.44 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/it/documents/overview/pemetrexed-lilly-epar-summary-public_it.pdf)

latviešu valoda (LV) (728.38 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/lv/documents/overview/pemetrexed-lilly-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (679.83 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/lt/documents/overview/pemetrexed-lilly-epar-summary-public_lt.pdf)

magyar (HU) (723.57 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/hu/documents/overview/pemetrexed-lilly-epar-summary-public_hu.pdf)

Malti (MT) (728.61 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/mt/documents/overview/pemetrexed-lilly-epar-summary-public_mt.pdf)

Nederlands (NL) (661.26 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/nl/documents/overview/pemetrexed-lilly-epar-summary-public_nl.pdf)

polski (PL) (727.02 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/pl/documents/overview/pemetrexed-lilly-epar-summary-public_pl.pdf)

português (PT) (661.63 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/pt/documents/overview/pemetrexed-lilly-epar-summary-public_pt.pdf)

română (RO) (678.76 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/ro/documents/overview/pemetrexed-lilly-epar-summary-public_ro.pdf)

slovenčina (SK) (727.84 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/sk/documents/overview/pemetrexed-lilly-epar-summary-public_sk.pdf)

slovenščina (SL) (720.72 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/sl/documents/overview/pemetrexed-lilly-epar-summary-public_sl.pdf)

Suomi (FI) (660.75 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/fi/documents/overview/pemetrexed-lilly-epar-summary-public_fi.pdf)

svenska (SV) (689.22 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/sv/documents/overview/pemetrexed-lilly-epar-summary-public_sv.pdf)

Pemetrexed Lilly : EPAR - Risk-management-plan summary

Reference Number: EMA/512407/2015

English (EN) (660.07 KB - PDF)

**First published:** 02/10/2015

**Last updated:** 26/11/2021

[View](/en/documents/rmp-summary/pemetrexed-lilly-epar-risk-management-plan-summary_en.pdf)

## Product information

Pemetrexed Lilly : EPAR - Product Information

English (EN) (1.49 MB - PDF)

**First published:** 02/10/2015

**Last updated:** 26/11/2021

[View](/en/documents/product-information/pemetrexed-lilly-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-547)

български (BG) (2.44 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/bg/documents/product-information/pemetrexed-lilly-epar-product-information_bg.pdf)

español (ES) (965.5 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/es/documents/product-information/pemetrexed-lilly-epar-product-information_es.pdf)

čeština (CS) (1.96 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/cs/documents/product-information/pemetrexed-lilly-epar-product-information_cs.pdf)

dansk (DA) (1.41 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/da/documents/product-information/pemetrexed-lilly-epar-product-information_da.pdf)

Deutsch (DE) (1.2 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/de/documents/product-information/pemetrexed-lilly-epar-product-information_de.pdf)

eesti keel (ET) (1.22 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/et/documents/product-information/pemetrexed-lilly-epar-product-information_et.pdf)

ελληνικά (EL) (2.58 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/el/documents/product-information/pemetrexed-lilly-epar-product-information_el.pdf)

français (FR) (1.22 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/fr/documents/product-information/pemetrexed-lilly-epar-product-information_fr.pdf)

hrvatski (HR) (1.24 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/hr/documents/product-information/pemetrexed-lilly-epar-product-information_hr.pdf)

íslenska (IS) (1.19 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/is/documents/product-information/pemetrexed-lilly-epar-product-information_is.pdf)

italiano (IT) (1.04 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/it/documents/product-information/pemetrexed-lilly-epar-product-information_it.pdf)

latviešu valoda (LV) (1.89 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/lv/documents/product-information/pemetrexed-lilly-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.31 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/lt/documents/product-information/pemetrexed-lilly-epar-product-information_lt.pdf)

magyar (HU) (1.97 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/hu/documents/product-information/pemetrexed-lilly-epar-product-information_hu.pdf)

Malti (MT) (1.87 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/mt/documents/product-information/pemetrexed-lilly-epar-product-information_mt.pdf)

Nederlands (NL) (1.21 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/nl/documents/product-information/pemetrexed-lilly-epar-product-information_nl.pdf)

norsk (NO) (1.27 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/no/documents/product-information/pemetrexed-lilly-epar-product-information_no.pdf)

polski (PL) (2.01 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/pl/documents/product-information/pemetrexed-lilly-epar-product-information_pl.pdf)

português (PT) (1.3 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/pt/documents/product-information/pemetrexed-lilly-epar-product-information_pt.pdf)

română (RO) (1.08 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/ro/documents/product-information/pemetrexed-lilly-epar-product-information_ro.pdf)

slovenčina (SK) (1.9 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/sk/documents/product-information/pemetrexed-lilly-epar-product-information_sk.pdf)

slovenščina (SL) (1.87 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/sl/documents/product-information/pemetrexed-lilly-epar-product-information_sl.pdf)

Suomi (FI) (1.16 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/fi/documents/product-information/pemetrexed-lilly-epar-product-information_fi.pdf)

svenska (SV) (1.48 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

26/11/2021

[View](/sv/documents/product-information/pemetrexed-lilly-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0013 18/06/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pemetrexed Lilly : EPAR - All authorised presentations

English (EN) (585.49 KB - PDF)

**First published:** 26/11/2021

[View](/en/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_en.pdf-0)

[Other languages (24)](#file-language-dropdown-884)

български (BG) (725.49 KB - PDF)

**First published:**

26/11/2021

[View](/bg/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_bg.pdf-0)

español (ES) (575.24 KB - PDF)

**First published:**

26/11/2021

[View](/es/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_es.pdf-0)

čeština (CS) (604.58 KB - PDF)

**First published:**

26/11/2021

[View](/cs/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_cs.pdf-0)

dansk (DA) (594.79 KB - PDF)

**First published:**

26/11/2021

[View](/da/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_da.pdf-0)

Deutsch (DE) (573.65 KB - PDF)

**First published:**

26/11/2021

[View](/de/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_de.pdf-0)

eesti keel (ET) (574.24 KB - PDF)

**First published:**

26/11/2021

[View](/et/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_et.pdf-0)

ελληνικά (EL) (635.28 KB - PDF)

**First published:**

26/11/2021

[View](/el/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_el.pdf-0)

français (FR) (574.84 KB - PDF)

**First published:**

26/11/2021

[View](/fr/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_fr.pdf-0)

hrvatski (HR) (588.11 KB - PDF)

**First published:**

26/11/2021

[View](/hr/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_hr.pdf-0)

íslenska (IS) (573.61 KB - PDF)

**First published:**

26/11/2021

[View](/is/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_is.pdf-0)

italiano (IT) (576.26 KB - PDF)

**First published:**

26/11/2021

[View](/it/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_it.pdf-0)

latviešu valoda (LV) (610.68 KB - PDF)

**First published:**

26/11/2021

[View](/lv/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_lv.pdf-0)

lietuvių kalba (LT) (587.51 KB - PDF)

**First published:**

26/11/2021

[View](/lt/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_lt.pdf-0)

magyar (HU) (596.31 KB - PDF)

**First published:**

26/11/2021

[View](/hu/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_hu.pdf-0)

Malti (MT) (609.08 KB - PDF)

**First published:**

26/11/2021

[View](/mt/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_mt.pdf-0)

Nederlands (NL) (575.14 KB - PDF)

**First published:**

26/11/2021

[View](/nl/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_nl.pdf-0)

norsk (NO) (576.62 KB - PDF)

**First published:**

26/11/2021

[View](/no/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_no.pdf-0)

polski (PL) (624.08 KB - PDF)

**First published:**

26/11/2021

[View](/pl/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_pl.pdf-0)

português (PT) (572.75 KB - PDF)

**First published:**

26/11/2021

[View](/pt/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_pt.pdf-0)

română (RO) (591.07 KB - PDF)

**First published:**

26/11/2021

[View](/ro/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_ro.pdf-0)

slovenčina (SK) (604.95 KB - PDF)

**First published:**

26/11/2021

[View](/sk/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_sk.pdf-0)

slovenščina (SL) (606.91 KB - PDF)

**First published:**

26/11/2021

[View](/sl/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_sl.pdf-0)

Suomi (FI) (575.29 KB - PDF)

**First published:**

26/11/2021

[View](/fi/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_fi.pdf-0)

svenska (SV) (592.05 KB - PDF)

**First published:**

26/11/2021

[View](/sv/documents/all-authorised-presentations/pemetrexed-lilly-epar-all-authorised-presentations_sv.pdf-0)

## Product details

Name of medicine Pemetrexed Lilly Active substance pemetrexed International non-proprietary name (INN) or common name pemetrexed Therapeutic area (MeSH)

- Carcinoma, Non-Small-Cell Lung
- Mesothelioma

Anatomical therapeutic chemical (ATC) code L01BA04

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Malignant pleural mesothelioma

Pemetrexed Lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

Non-small cell lung cancer

Pemetrexed Lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Pemetrexed Lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.

## Authorisation details

EMA product number EMEA/H/C/004114

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Eli Lilly Netherlands

Grootslag 1-5

Marketing authorisation issued 14/09/2015 Revision 7

## Assessment history

## Changes since initial authorisation of medicine

Pemetrexed Lilly : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (764.11 KB - PDF)

**First published:** 29/02/2016

**Last updated:** 26/11/2021

[View](/en/documents/procedural-steps-after/pemetrexed-lilly-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

#### News on Pemetrexed Lilly

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2015) 24/07/2015

#### More information on Pemetrexed Lilly

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 26/11/2021

## Share this page

[Back to top](#main-content)